News
(Reuters) -Wall Street's top regulator the U.S. Securities and Exchange Commission saw the biggest drop in staff numbers at ...
The private-equity firm’s goal for its 10th flagship fund is as much as 13% lower than the target set for a predecessor, ...
One 2025 high school graduate in Louisiana is the only one in her class to graduate, being the only person in her school in ...
As Warren Buffett steps back, some of the world’s biggest money managers will try to keep building on his legacy. They ...
After warnings that the dragged-out process was putting the cell therapy company at risk of bankruptcy, bluebird bio now has ...
Six years after Merck bought out Peloton Therapeutics, the New Jersey drugmaker is not remaining stationary with the crown ...
Australia's Insignia Financial said on Wednesday that Bain Capital has pulled its buyout offer due to volatile financial ...
Irvine, California-based the New Home Company is acquiring Dallas-based Landsea at $11.30 per share in an all-cash ...
For investors in gene therapy biotech bluebird bio, a wait-and-see approach toward a proposed acquisition has paid off. | For ...
KENMARE Resources has been granted an extension for ongoing acquisition talks with potential buyers, pushing the decision ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results